FDA Grants RMAT Designation to ETX101 for Dravet Syndrome
Encoded Therapeutics Inc. has announced that the U.S. FDA has granted Regenerative Medicine Advanced Therapy…
Newswire
Leadership Changes at Novo Nordisk and Rocket Pharma
Recent leadership transitions at Novo Nordisk and Rocket Pharma have raised significant attention within the…
Physician Enthusiasm for Novo’s Wegovy Suggests Swift Uptake in Rezdiffra-Dominated MASH Market
Recent surveys conducted by Spherix indicate a notable enthusiasm among physicians for Novo’s Wegovy, particularly…
AbbVie’s Gilgamesh Acquisition: A Strategic Shift to Single-Asset Focus
AbbVie has recently made headlines with its acquisition of Gilgamesh Pharmaceuticals, underscoring a growing trend…
Zydus Therapeutics Secures Phase 2b/3 Victory in Liver Disease: A Strategic Move Against Gilead and Ipsen
Zydus Therapeutics has achieved a significant milestone with its phase 2b/3 trial success in treating…
BeOne Advances Sonrotoclax: A Potential Breakthrough in Rare B Cell Lymphoma Treatment
BeOne Medicines has announced promising topline results from its Phase 1/2 trial of sonrotoclax, a…
Outlook’s Wet AMD Candidate Faces Second FDA Rejection
Outlook Therapeutics has received a second rejection from the FDA for its wet age-related macular…
A New Dawn for GCA Treatment
In the realm of chronic autoimmune disorders, giant cell arteritis (GCA) has long been a…
Turning Cancer on Its Head
Cancer cells are no longer just enemies, but unwilling partners in their own defeat. This…
FDA’s Bold Move: Pfizer’s EUA Revoked
In a surprising twist, the FDA has pulled the emergency use authorization for Pfizer’s Covid…